



# Commonly Prescribed HIV Medications









## Single-Tablet Regimens

<p><b>Atripla</b> (efavirenz/emtricitabine/ tenofovir disoproxil fumarate)</p> 	<p><b>Biktarvy</b> (bictegravir/emtricitabine/ tenofovir alafenamide)</p> 	<p><b>Complera</b> (rilpivirine/emtricitabine/ tenofovir disoproxil fumarate)</p> 	<p><b>Delstrigo</b> (doravirine/lamivudine/ tenofovir disoproxil fumarate)</p> 	<p><b>Dovato</b> (dolutegravir + lamivudine)</p> 	<p><b>Genvoya</b> (elvitegravir/cobicistat/ emtricitabine/ tenofovir alafenamide)</p> 	<p><b>Juluca</b> (dolutegravir/rilpivirine)</p> 	<p><b>Odefsey</b> (emtricitabine/rilpivirine/ tenofovir alafenamide)</p> 	<p><b>Stribild</b> (elvitegravir/cobicistat/ emtricitabine/tenofovir disoproxil fumarate)</p> 	<p><b>Symfi/Symfi Lo</b> (efavirenz/lamivudine/ tenofovir disoproxil fumarate)</p> 
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------




## Single-Tablet Regimens (cont.)

<p><b>Symtuza</b> (darunavir/cobicistat/ emtricitabine/tenofovir alafenamide)</p> 	<p><b>Triumeq</b> (dolutegravir/abacavir/ lamivudine)</p> 
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------



## Nucleoside/Nucleotide Analogs (NRTIs)

<p><b>Cimduo/Temixys</b> (lamivudine/tenofovir disoproxil fumarate)</p> 	<p><b>Descovy</b> (emtricitabine/tenofovir alafenamide)</p> 	<p><b>Emtriva</b> (emtricitabine or FTC)</p> 	<p><b>Epivir</b> (lamivudine or 3TC)</p> 	<p><b>Epzicom</b> (abacavir/lamivudine)</p> 	<p><b>Truvada</b> (emtricitabine/tenofovir disoproxil fumarate)</p> 	<p><b>Viread</b> (tenofovir disoproxil fumarate or TDF)</p> 	<p><b>Ziagen</b> (abacavir or ABC)</p> 
-------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------



## Protease Inhibitors (PIs)

<p><b>Evotaz</b> (atazanavir/cobicistat)</p> 	<p><b>Prezcobix</b> (darunavir/cobicistat)</p> 	<p><b>Prezista</b> (darunavir or DRV)</p> 	<p><b>Reyataz</b> (atazanavir or ATV)</p> 
--------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------



## Non-Nucleosides (NNRTIs)

<p><b>Edurant</b> (rilpivirine or RPV)</p> 	<p><b>Intellec</b> (etravirine or ETV)</p> 	<p><b>Pifeltro</b> (doravirine)</p> 	<p><b>Sustiva</b> (efavirenz or EFV)</p> 
--------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------



## Pre-Exposure Prophylaxis (PrEP)

<p><b>Truvada</b> (emtricitabine/tenofovir disoproxil fumarate)</p> 	<p><b>Descovy</b> (emtricitabine/tenofovir alafenamide)</p>  <p>Not indicated for individuals at risk from receptive vaginal sex.</p>
-----------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



## Integrase Inhibitors

<p><b>Isentress</b> (raltegravir or RAL)</p> 	<p><b>Tivicay</b> (dolutegravir or DTG)</p> 
---------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------


## Pharmacokinetic Enhancers

<p><b>Norvir</b> (ritonavir or RTV)</p> 	<p><b>Tyboost</b> (cobicistat)</p> 
-----------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------

## Entry Inhibitors

<p><b>Selzentry</b> (maraviroc or MVC)</p> 	<p><b>Trogarzo</b> (ibalizumab-uiyk) <small>(for injection)</small></p> 
--------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------

## HIV Life Cycle and Medication Action Sites



Simplified diagram showing human immunodeficiency virus (HIV) replication and the mechanisms of action of antiretroviral drug classes.

## Less Frequently Prescribed HIV Medications

### Nucleoside/Nucleotide Analogs (NRTIs)

<b>Combivir</b> (zidovudine/lamivudine) 	<b>Retrovir</b> (zidovudine ZDV or AZT) 	<b>Trizivir</b> (abacavir/lamivudine/zidovudine) 	<b>Videx, Videx EC</b> (didanosine or ddl) 	<b>Zerit</b> (stavudine or d4T) 
------------------------------------------------	------------------------------------------------	---------------------------------------------------------	---------------------------------------------------	----------------------------------------

### Protease Inhibitors (PIs)

<b>Aptivus</b> (tipranavir or TPV) 	<b>Crixivan</b> (indinavir or IDV) 	<b>Invirase</b> (saquinavir or SQV) 	<b>Kaletra</b> (lopinavir/ritonavir) 	<b>Lexiva</b> (fosamprenavir or FPV) 	<b>Viracept</b> (nelfinavir or NFV) 
-------------------------------------------	-------------------------------------------	--------------------------------------------	---------------------------------------------	---------------------------------------------	--------------------------------------------

### Non-Nucleosides (NNRTIs)

<b>Rescriptor</b> (delavirdine or DLV) 	<b>Viramune</b> (nevirapine or NVP) 
-----------------------------------------------	--------------------------------------------

### Entry Inhibitors

<b>Fuzeon</b> (enfuvirtide or ENF) (for injection) 
--------------------------------------------------------------

### Integrase Inhibitors

<b>Vitekta</b> (elvitegravir) 
--------------------------------------

Community Research Initiative of New England (CRI) is an independent, nonprofit, community-based organization dedicated to ending the HIV epidemic through:

- ▶ **Research:** Conducting HIV/AIDS and hepatitis C clinical trials.
- ▶ **Prevention:** Limiting new HIV cases through education and access to biomedical prevention strategies like PrEP.
- ▶ **Access to Treatment:** Providing access to medications, health insurance coverage, and health benefits information to people who have infectious diseases.
- ▶ **Impact:** Disseminating state-of-the-art treatment and insurance training and consultation.

Since 1989, CRI has produced critical data that has contributed to the FDA approval of nearly all of the currently available HIV treatments and forever changed the direction of HIV/AIDS treatment around the world.

Through its management of the Massachusetts Infectious Disease Drug Assistance Program (IDDAP), CRI provides access to medications and health insurance coverage to more than 8,000 Massachusetts residents living with HIV or taking preventive treatment. Through its continued outreach efforts, CRI provides the latest treatment information to people living with HIV, hepatitis C, and other infectious diseases.

### About the medication chart

CRI produces the medication chart with funding from the Bureau of Infectious Disease, Office of HIV/AIDS, Massachusetts Department of Public Health. It displays and names all formulations of each HIV or HCV medication currently or recently available. Medications on the chart are listed in the following manner:

- ▶ Grouped by class
- ▶ Commercial brand name in **bold**
- ▶ Formal clinical name (in parentheses), which may also be the name used in studies/trials before a medication received FDA approval and became available to the public

CRI updates the chart as needed, with the date of each version noted. Copies are available upon request. For more information or to order copies of the chart, please contact the CRI Development and Communications office at [info@crine.org](mailto:info@crine.org) or 617.502.1726.

Visit our website at [www.crine.org](http://www.crine.org)

529 Main Street, Suite 301, Boston, MA 02129  
617.502.1700



# HIV Medication Chart

Current as of 11/19

617.502.1700 | [www.crine.org](http://www.crine.org)